AddLife Valuation
Is ALIF B undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of ALIF B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: ALIF B (SEK155.6) is trading below our estimate of fair value (SEK208.7)
Significantly Below Fair Value: ALIF B is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ALIF B?
Other financial metrics that can be useful for relative valuation.
What is ALIF B's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | SEK 18.96b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 2.4x |
Enterprise Value/EBITDA | 21.8x |
PEG Ratio | 2.9x |
Price to Sales Ratio vs Peers
How does ALIF B's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 7.2x | ||
BIOT Biotage | 7.4x | 10.8% | SEK 15.4b |
MCAP MedCap | 5x | n/a | SEK 8.8b |
BICO BICO Group | 1.3x | 7.8% | SEK 3.0b |
GENO Genovis AB (publ.) | 15x | 19.9% | SEK 1.9b |
ALIF B AddLife | 1.9x | 7.0% | SEK 19.0b |
Price-To-Sales vs Peers: ALIF B is good value based on its Price-To-Sales Ratio (1.9x) compared to the peer average (7.2x).
Price to Earnings Ratio vs Industry
How does ALIF B's PE Ratio compare vs other companies in the European Life Sciences Industry?
Price-To-Sales vs Industry: ALIF B is good value based on its Price-To-Sales Ratio (1.9x) compared to the European Life Sciences industry average (5x).
Price to Sales Ratio vs Fair Ratio
What is ALIF B's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 1.9x |
Fair PS Ratio | 3.4x |
Price-To-Sales vs Fair Ratio: ALIF B is good value based on its Price-To-Sales Ratio (1.9x) compared to the estimated Fair Price-To-Sales Ratio (3.4x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | SEK 155.60 | SEK 168.00 +8.0% | 1.8% | SEK 171.00 | SEK 165.00 | n/a | 2 |
Jul ’25 | SEK 125.30 | SEK 142.50 +13.7% | 2.5% | SEK 146.00 | SEK 139.00 | n/a | 2 |
Jun ’25 | SEK 114.40 | SEK 137.00 +19.8% | 1.5% | SEK 139.00 | SEK 135.00 | n/a | 2 |
May ’25 | SEK 102.60 | SEK 137.00 +33.5% | 1.5% | SEK 139.00 | SEK 135.00 | n/a | 2 |
Apr ’25 | SEK 112.00 | SEK 136.50 +21.9% | 4.8% | SEK 143.00 | SEK 130.00 | n/a | 2 |
Mar ’25 | SEK 102.40 | SEK 136.50 +33.3% | 4.8% | SEK 143.00 | SEK 130.00 | n/a | 2 |
Feb ’25 | SEK 111.80 | SEK 132.00 +18.1% | 1.5% | SEK 134.00 | SEK 130.00 | n/a | 2 |
Jan ’25 | SEK 109.40 | SEK 111.00 +1.5% | 9.9% | SEK 122.00 | SEK 100.00 | n/a | 2 |
Dec ’24 | SEK 97.30 | SEK 111.00 +14.1% | 9.9% | SEK 122.00 | SEK 100.00 | n/a | 2 |
Nov ’24 | SEK 73.35 | SEK 118.00 +60.9% | 15.3% | SEK 136.00 | SEK 100.00 | n/a | 2 |
Oct ’24 | SEK 64.75 | SEK 135.50 +109.3% | 0.4% | SEK 136.00 | SEK 135.00 | n/a | 2 |
Sep ’24 | SEK 75.50 | SEK 135.50 +79.5% | 0.4% | SEK 136.00 | SEK 135.00 | n/a | 2 |
Aug ’24 | SEK 85.10 | SEK 135.50 +59.2% | 0.4% | SEK 136.00 | SEK 135.00 | n/a | 2 |
Jul ’24 | SEK 121.70 | SEK 152.50 +25.3% | 1.6% | SEK 155.00 | SEK 150.00 | SEK 125.30 | 2 |
May ’24 | SEK 121.20 | SEK 137.50 +13.4% | 1.8% | SEK 140.00 | SEK 135.00 | SEK 102.60 | 2 |
Analyst Forecast: Target price is less than 20% higher than the current share price.